Literature DB >> 33658187

Treatment effects in randomised trials using routinely collected data for outcome assessment versus traditional trials: meta-research study.

Kimberly A Mc Cord1, Hannah Ewald1,2, Arnav Agarwal3, Dominik Glinz1, Soheila Aghlmandi1, John P A Ioannidis4,5, Lars G Hemkens6,7,5.   

Abstract

OBJECTIVE: To compare effect estimates of randomised clinical trials that use routinely collected data (RCD-RCT) for outcome ascertainment with traditional trials not using routinely collected data.
DESIGN: Meta-research study. DATA SOURCE: Studies included in the same meta-analysis in a Cochrane review. ELIGIBILITY CRITERIA FOR STUDY SELECTION: Randomised clinical trials using any type of routinely collected data for outcome ascertainment, including from registries, electronic health records, and administrative databases, that were included in a meta-analysis of a Cochrane review on any clinical question and any health outcome together with traditional trials not using routinely collected data for outcome measurement. REVIEW
METHODS: Effect estimates from trials using or not using routinely collected data were summarised in random effects meta-analyses. Agreement of (summary) treatment effect estimates from trials using routinely collected data and those not using such data was expressed as the ratio of odds ratios. Subgroup analyses explored effects in trials based on different types of routinely collected data. Two investigators independently assessed the quality of each data source.
RESULTS: 84 RCD-RCTs and 463 traditional trials on 22 clinical questions were included. Trials using routinely collected data for outcome ascertainment showed 20% less favourable treatment effect estimates than traditional trials (ratio of odds ratios 0.80, 95% confidence interval 0.70 to 0.91, I2=14%). Results were similar across various types of outcomes (mortality outcomes: 0.92, 0.74 to 1.15, I2=12%; non-mortality outcomes: 0.71, 0.60 to 0.84, I2=8%), data sources (electronic health records: 0.81, 0.59 to 1.11, I2=28%; registries: 0.86, 0.75 to 0.99, I2=20%; administrative data: 0.84, 0.72 to 0.99, I2=0%), and data quality (high data quality: 0.82, 0.72 to 0.93, I2=0%).
CONCLUSIONS: Randomised clinical trials using routinely collected data for outcome ascertainment show smaller treatment benefits than traditional trials not using routinely collected data. These differences could have implications for healthcare decision making and the application of real world evidence. © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Year:  2021        PMID: 33658187     DOI: 10.1136/bmj.n450

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  8 in total

1.  Generalizability and reach of a randomized controlled trial to improve oral health among home care recipients: comparing participants and nonparticipants at baseline and during follow-up.

Authors:  Jonas Czwikla; Alexandra Herzberg; Sonja Kapp; Stephan Kloep; Heinz Rothgang; Ina Nitschke; Cornelius Haffner; Falk Hoffmann
Journal:  Trials       Date:  2022-07-08       Impact factor: 2.728

Review 2.  The need for increased pragmatism in cardiovascular clinical trials.

Authors:  Muhammad Shariq Usman; Harriette G C Van Spall; Stephen J Greene; Ambarish Pandey; Darren K McGuire; Ziad A Ali; Robert J Mentz; Gregg C Fonarow; John A Spertus; Stefan D Anker; Javed Butler; Stefan K James; Muhammad Shahzeb Khan
Journal:  Nat Rev Cardiol       Date:  2022-05-17       Impact factor: 49.421

Review 3.  Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials.

Authors:  Yoon Duk Hong; Jeroen P Jansen; John Guerino; Marc L Berger; William Crown; Wim G Goettsch; C Daniel Mullins; Richard J Willke; Lucinda S Orsini
Journal:  BMC Med       Date:  2021-12-06       Impact factor: 8.775

4.  Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial.

Authors:  Monika K Krzyzanowska; Jim A Julian; Chu-Shu Gu; Melanie Powis; Qing Li; Katherine Enright; Doris Howell; Craig C Earle; Sonal Gandhi; Sara Rask; Christine Brezden-Masley; Susan Dent; Leena Hajra; Orit Freeman; Silvana Spadafora; Caroline Hamm; Nadia Califaretti; Maureen Trudeau; Mark N Levine; Eitan Amir; Louise Bordeleau; James A Chiarotto; Christine Elser; Juhi Husain; Nicole Laferriere; Yasmin Rahim; Andrew G Robinson; Ted Vandenberg; Eva Grunfeld
Journal:  BMJ       Date:  2021-12-08

5.  A Scoping Review on Use of Drugs Targeting the JAK/STAT Pathway in Psoriasis.

Authors:  Francisco Gómez-García; Pedro Jesús Gómez-Arias; Ana Montilla-López; Jorge Hernández-Parada; Juan Luís Sanz-Cabanillas; Juan Ruano; Esmeralda Parra-Peralbo
Journal:  Front Med (Lausanne)       Date:  2022-02-25

6.  Impact of systematic medication review in emergency department on patients' post-discharge outcomes-A randomized controlled clinical trial.

Authors:  Lisbeth Damlien Nymoen; Trude Eline Flatebø; Tron Anders Moger; Erik Øie; Espen Molden; Kirsten Kilvik Viktil
Journal:  PLoS One       Date:  2022-09-19       Impact factor: 3.752

7.  The Helpfulness of Web-Based Mental Health and Well-being Forums for Providing Peer Support for Young People: Cross-sectional Exploration.

Authors:  Emily Banwell; Terry Hanley; Santiago De Ossorno Garcia; Charlotte Mindel; Thomas Kayll; Aaron Sefi
Journal:  JMIR Form Res       Date:  2022-09-09

8.  Randomised controlled trials in hand surgery: a scoping review.

Authors:  Juuso Heikkinen; Soumen Das De; Jarkko Jokihaara; Kati Jaatinen; Rachelle Buchbinder; Teemu Karjalainen
Journal:  BMJ Open       Date:  2022-10-10       Impact factor: 3.006

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.